Patent Landscaping for Vaccines: Patent information, tools and methodologies Martin Friede Ph.D. **Initiative for Vaccine Research**



Patent Landscaping within WHO/IVR


- To promote the development and production of vaccines by developing-country vaccine manufacturers.
- Identifying where IP is a barrier to access for vaccines
- Support research on alternative technologies
- Identify technology areas to promote where IP is not a barrier



World Health

The complexity of vaccine IP

 A modern vaccine is protected by multiple levels of IP often licensed from multiple partners







Why vaccines are different to drugs

True 'generic' vaccines do not exist

 Complex biological drugs: equivalence can not be demonstrated by simple tests. Full clinical safety and efficacy (or surrogate) testing of 'copy' required.



World Health

Top-down or Bottom-up approach ?

Top-down: landscape entire field (eg. 'Influenza Vaccine')

- Large number of 'hits'
- Does not require detailed technical knowledge of topic
- Value: an idea of where field is going, areas of IP coverage
- Bottom up: search <u>claims</u> on specific concepts
 - Value: identify potential FTO issues.
 - Fewer hits
 - Knowledge intensive: requires detailed technical understanding of topic being researched.
 - Labour intensive: requires reading and interpreting claims



World Health

Example: Influenza Production Methods

http://www.who.int/vaccine_research/diseases/influenza/Mapping_Intellectual_Property_Pandemic_Influenza_Vaccines.pdf

- Objective: assist developing-country vaccine manufacturers identify most appropriate technology or licensing partner.
 - Numerous ways to make influenza vaccines (technical document)
- Landscape method: bottom-up
 - For each <u>known</u> process / composition of matter:
 - Search keywords in <u>claims</u> in EU and US application and granted patents
 - Identify relevant claims, identify legal status (Inpadoc: EU / US)
 - From PCT application see designated countries
 - DC Manufacturer advised to see if application exists in their country.

Tool used: Cambia's Patent Lens (search on claims)



Example: Human Papilloma Virus

- Objective: Interest from DC vaccine manufacturers to make HPV vaccine for developing countries. Need to know if such projects viable to fund (FTO issue)
- Landscape method: mix of top-down and bottom-up
 - A) Overview of IP on HPV
 - Outsourced search (Derwent)
 - B) identify IP claiming critical components of approved HPV vaccine
 - Search on claims for HPV gene sequence, vaccine comprising,.. Patent Lens
 - Identify interference/opposition proceedings
 - C) look for equivalents in India, China, Brazil : country office





World Health

Issues encountered

Claim analysis

- Need to know whether US/EU equivalent in developing country.
 - Inpadoc not reliable / up to date.
 - Need in-country evaluation of local IP situation.
 - Country of manufacture, intended countries for export...
 - Claims
- Analysis of expiry dates critical
 - For vaccines development time long
 - Policy issue: support R&D on antigens / adjuvants nearing end of pate life.
 - Need to consider 'method of use' patent-life extension



Issues encountered

- Country-request is often for FTO identification: legal opinion
 - Can only help with identifying some non-exhaustive IP which should be considered.
- Insufficient capacity in developing countries with respect to:
 - Patent lawyers with understanding of the science behind the technology
 - Scientists with understanding of IP searching and interpreting



World Health

Landscaping Issues

Define the question !

- Landscaping only as good as description of technology to landscaper
 - Need close collaboration between technology expert and IP expert
- Public health community has inadequate knowledge of IP
 - 'Interpret' patent based on abstract or disclosure, not claims.
 - Often do not realize territorial/ temporal limitation



World Health

Observations

- For vaccines, legal FTO is only small part of barrier to access for developing country manufacturers:
 - Other IP: know-how, clinical data, regulatory dossiers
 - Licensing often preferable to developing product *ab-initio*.
- Developing alternative processes for process patents requires R&D capacity.
 - DC vaccine manufacturers need to invest in this area.





World Health